NULISA

ALZpath and Alamar Biosciences are expanding their pTau217 collaboration to support the development of blood-based clinical diagnostics for Alzheimer’s disease, as laboratories pursue more accessible biomarker testing pathways. Representative image.

Medical Devices & Diagnostics

ALZpath just gave Alamar a bigger Alzheimer’s diagnostics role, but the regulatory test starts now

by Pallavi Madhiraju
July 27, 2026
0 Comments

ALZpath expands its Alamar Biosciences deal into clinical diagnostics, opening a new path for pTau217 blood tests in Alzheimer’s disease.

Read More